金奧博(002917.SZ):泰山民爆第一期和第二期生產線改造建設已通過驗收正式投產
格隆匯2月1日丨金奧博(002917.SZ)於近日接受特定對象調研,就“2023年行業電子雷管整體情況以及公司產線建設和市場情況?”,公司回覆稱,2023年,行業生產企業電子雷管累計產量為6.7億發,同比增加94.9%。公司積極推進產線併線技術改造,建立電子雷管產能規模優勢,實現擴能擴產,截至2023年12月,泰山民爆第一期和第二期生產線改造建設已通過驗收正式投產。公司電子雷管產銷量在穩步提升中,同時公司在不斷加強產品銷售推廣,擴大市場份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.